Vertex Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
August 4, 2025 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.52, $0.25 better than the analyst estimate of $4.27. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of... More
